ImmunityBio, Inc. (IBRX)

9,33 +0,36 (+4,01%) In data: 09:38AM EDT. Mercato aperto.

ImmunityBio, Inc.

3530 John Hopkins Court
San Diego, CA 92121
United States
844 696 5235
https://immunitybio.com

Settore/i: Healthcare
Settore: Biotechnology
Impiegati a tempo pieno: 628

Figure dirigenziali chiave

Nome	Titolo	Retribuzione	Esercitate	Anno di nascita
Mr. Richard Gerald Adcock	President, CEO & Director	849,45k	N/D	1969
Dr. Barry J. Simon M.D.	Chief Corporate Affairs Officer & Director	N/D	N/D	1965
Dr. Leonard S. Sender M.D.	Chief Operating Officer	N/D	N/D	N/D
Ms. Elizabeth S. Gabitzsch	Senior Vice President of Product Development & Vaccine Programs	N/D	N/D	N/D
Dr. Manju Saxena Ph.D.	SVP of Product Development & Cell Therapy Program	N/D	N/D	N/D

Gli importi risalgono al giorno 31 dicembre 2022 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in USD.

Descrizione

ImmunityBio, Inc., a clinical-stage biotechnology company, engages in discovering, developing, and commercializing next-generation immuno- and cellular therapies for cancer and infectious diseases in the United States and Europe. The company offers immunotherapy and cell therapy platforms, including antibody cytokine fusion protein N-803, vaccine delivery technologies, and natural killer cell therapies. Its lead biologic commercial product candidate is Anktiva, an IL-15 superagonist antibody-cytokine fusion protein for the treatment of bacillus Calmette-Guérin-unresponsive non-muscle invasive bladder cancer with carcinoma in situ with or without Ta or T1 disease. The company also develops other therapeutic agents for the treatment of liquid and solid tumors, including bladder, lung, colorectal, and ovarian cancers, as well as glioblastoma multiforme, acute myeloid leukemia, and human immunodeficiency virus. It has collaboration agreements with National Cancer Institute and Amyris, Inc.; and license agreements with LadRx Corporation, GlobeImmune, Inc., Access to Advanced Health Institute, 3M Innovative Properties Company, Sanford Health, Shenzhen Beike Biotechnology Co. Ltd., and Viracta Therapeutics, Inc. The company is based in San Diego, California.

Governance aziendale

L'ISS Governance QualityScore di ImmunityBio, Inc. al 1 maggio 2024 è 8. I criteri di valutazione fondamentali sono revisione: 8; Consiglio di Amministrazione: 9; diritti degli azionisti: 6; retribuzione: 7.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.